Classification of Asthma Exacerbations

Primary Classification System

The American Academy of Allergy, Asthma, and Immunology recommends classifying asthma exacerbations into four severity categories—mild, moderate, severe, or life-threatening—based primarily on percent predicted FEV₁ or peak expiratory flow (PEF), with additional assessment of symptoms, physical examination findings, and oxygen saturation 1
The primary determinant of asthma exacerbation severity is lung function measured as percent predicted FEV₁ or PEF, according to the National Asthma Education and Prevention Program (NAEPP) 1

A mild exacerbation is characterized by a PEF of 70-90% of predicted or personal best, and can usually be managed at home 1
A moderate exacerbation is characterized by a PEF of 50-79% of predicted or personal best, and may require emergency department evaluation 1
A severe exacerbation is characterized by a PEF of less than 50% of predicted or personal best, and requires emergency department treatment and possible hospitalization 1
A life-threatening exacerbation is marked by severe respiratory distress, altered mental status, or inability to speak in phrases 1

Symptoms such as breathlessness, coughing, wheezing, and chest tightness intensity are used to support the classification of asthma exacerbations 1
Physical examination findings, including agitation, increased respiratory rate and pulse, use of accessory muscles, and inability to speak in complete sentences, are used to support the classification of asthma exacerbations 1
Oxygen saturation, including SaO₂ levels and arterial blood gas measurements (PaO₂, PaCO₂), is used to support the classification of asthma exacerbations 1

Patients with a history of previous severe exacerbation, including intubation or ICU admission, are at high risk and require special attention 1
Patients with two or more hospitalizations for asthma in the past year are at high risk and require special attention 1
Patients with three or more ED visits for asthma in the past year are at high risk and require special attention 1
Patients with recent hospitalization or ED visit within the past month are at high risk and require special attention 1
Patients with excessive SABA use, defined as more than two canisters per month, are at high risk and require special attention 1
Patients with difficulty perceiving symptoms or exacerbation severity are at high risk and require special attention 1
Patients without a written asthma action plan are at high risk and require special attention 1
Infants are at inherently greater risk and require special attention 1

Underestimating exacerbation severity or assuming well-controlled baseline asthma protects against severe exacerbations is a common and dangerous clinical error, according to the National Asthma Education and Prevention Program (NAEPP) 2
Relying solely on symptoms without objective lung function measurement can lead to misclassification of asthma exacerbations 3
Failing to recognize that patients with any baseline severity level can experience life-threatening exacerbations is a common pitfall to avoid 2
Not identifying high-risk patients who require more aggressive monitoring and intervention is a common pitfall to avoid, according to the American Academy of Allergy, Asthma, and Immunology 1, 2

The National Asthma Education and Prevention Program (NAEPP) specifies that percent‑predicted FEV₁ or peak expiratory flow (PEF) is the primary determinant of exacerbation severity, with clinical parameters serving as supporting evidence. 4

A moderate exacerbation is characterized by deterioration in symptoms, lung function, and increased rescue bronchodilator use lasting ≥ 2 days. 5
Management of a moderate exacerbation requires a temporary change in treatment to prevent progression to severe disease. 6
Emergency‑department visits for moderate exacerbations may occur without the need for systemic corticosteroids. 5

A severe exacerbation is defined by the requirement for systemic corticosteroids for at least 3 days, or by hospitalization/ED visit that necessitates systemic corticosteroids. 5

Life‑threatening exacerbations necessitate immediate aggressive intervention and consideration for ICU admission. 4
Altered mental status or reduced level of alertness is a critical clinical indicator of a life‑threatening episode. 4

Wheezing is an unreliable indicator of exacerbation severity and should not be used alone for classification. 4

Systemic corticosteroids should be considered for moderate exacerbations to prevent progression to severe disease. 5